Pennant Group is no longer a Western home-care spin living off the Ensign inheritance. The company is trying to prove that the same local-leader model can digest the largest acquisition in its history, the October purchase of fifty-four home health, hospice, and personal-care sites that UnitedHealth and Amedisys sold under an antitrust settlement. Second-quarter revenue reached $298 million. That print is the first clean look at whether Southeast volume arrived without breaking the established agencies that still set the quality of the earnings.
The tension sits in the mix rather than the headline growth rate. Same-agency home health and hospice revenue still grew 11 percent, which is the signal that the core machine did not stall while management ran transition waves. Segment growth of 43 percent is mostly acquired volume from Tennessee, Georgia, and Alabama. Adjusted earnings outran revenue, yet interest expense more than doubled as the credit facility funded both the deal and a new Connecticut equity stake. Cash conversion remains the weaker twin of the growth story.
Management raised full-year guidance after the quarter and said the company is on pace to clear the top of the original range. Senior living occupancy in the established book improved, while newly leased communities make segment margins uneven into year-end. Shares last changed hands near $40, or about $1.4 billion of equity, after a mid-September push toward the top of the yearly range. The open question is whether October's last transition wave and the hospice integrity rules leave a compounding platform, or a multiple that already assumed a clean close.